OrbiMed Closes Third Asia Private Equity Fund, at $551M

OrbiMed, a NYC-based investment firm focused on the healthcare sector, closed its third Asia-focused private equity fund, with approximately $551m in capital commitments.

Consistent with its predecessor funds, OrbiMed Asia Partners III, LP, will invest broadly across the Asian healthcare industry, with a focus on growth stage product- and services-oriented companies in China and India.
The fund will target investments from $10m to $75m per company across 15 to 20 opportunities.
Where appropriate, Asia Partners III may co-invest with OrbiMed’s global team, enabling larger investments and leveraging the full financial and strategic resources of OrbiMed’s 100+ team members and $14 billion global investment platform.

OrbiMed’s Shanghai office, opened in 2007, is led by Dr. Jonathan Wang and Dr. David Wang. The Mumbai office was opened in 2008 and is led by Senior Managing Director Dr. Sunny Sharma.

The firm also maintains offices in New York City, San Francisco, and Herzliya.



Join the discussion